09/03/2024 | Press release | Archived content
An international team led by our Athens team and involving also our London, Brussels and Milan teams together with teams from Walkers (Ireland) LLP in Dublin, Ireland, and Trilegal in Mumbai, India, advised the Sellers of the HeaDs Group in the sale of the Heads Group to the Veeda Group (www.veedacr.com).
The transaction included consideration in cash and equity in the Veeda Group. The consideration includes an earnout for the sellers. HeaDs is a full-service global contract research organization (CRO) specializing in conducting clinical trials in haemato-oncology and having corporate and operational presence in 25 multiple locations across Europe, North America and the Asia Pacific region. Veeda is an independent, full-service CRO headquartered in Ahmedabad, India with a strong record of bioequivalence studies and early and late phase clinical trials.
By this complex transaction, the Veeda Group acquired a complete range of clinical trial services, from Phase I to IV.
Our team advising on the transaction was led by Elena Tsohou assisted by Nikos Anagnostopoulos in Athens, James Parker, Dominic Stuttaford, Holly Stebbing, James Dunnett, Oliver Kabongo, Nonna Crane, Elisabeth Trotter, India Furse, Sunny Wong, Fiona Bundy-Clarke in London, Jay Modrall and Angelos Vlazakis in Brussels, and Attilio Pavone and Federico Moriconi in Milan.